[June 18, 2019]

Goodwin Continues Global Expansion of Life Sciences and Technology Practices with Four Market-Leading Partners in the United Kingdom

Global law firm Goodwin announced today that Malcolm Bates, David Mardle, Tim Worden and Adrian Rainey will join its Life Sciences and Technology Companies practices in the firm's London office. Mardle joined the firm yesterday, while Bates, Worden and Rainey will join following the completion of their notice periods.

• Malcolm Bates is among the leading life science licensing and collaboration lawyers in the UK and Europe. He advises on transactions, including licenses, collaborations and distribution, manufacturing, outsourcing and R&D projects, as well as regulatory matters and contract and patent disputes.
• David Mardle is a highly experienced corporate lawyer, having advised on private and public financings and M&A transactions in the life sciences and technology sectors for nearly 20 years.
• Tim Worden focuses on licensing and collaboration transactions, R&D and clinical trial agreements, and regulatory matters. His expertise also includes the IP and regulatory aspects of M&A transactions and public and private financings.
• Adrian Rainey is one of the leading corporate lawyers in the UK and Europe specializing in representing technology companies and venture capital firms. He advises on private financings and M&A transactions across the software, internet, financial technology and digital media industries, as well as in the life scinces and medical devices industries.

Goodwin represents leading public and private life sciences companies across their entire life cycles - including financings, capital market transactions, mergers and acquisitions, collaborations and licensing, intellectual property and regulatory matters. The firm has been named life sciences "Practice Group of the Year" by Law360, "Biotech Firm of the Year" by U.S. News and World Report - Best Lawyers, and "IP Law Firm of the Year" by LMG Life Sciences.

In 2018, Goodwin advised issuers on more than a dozen biotechnology and pharmaceutical industry IPOs worth in aggregate nearly $2 billion - making Goodwin the number one advisor in this sector by offering value. This work included representation of Moderna Therapeutics in the largest biotechnology IPO in history.

Goodwin's technology practice supports clients at all stages of the corporate life cycle. It is consistently recognized among the very best in the industry, including by Mergermarket, Bloomberg, PitchBook and Thomson (News - Alert) Reuters. Among other notable matters, the team recently advised Carbon Black on its IPO, and advised Qualtrics International on its acquisition by SAP (News - Alert) SE, for which it was named "Dealmaker of the Year" by The American Lawyer.

Over the past five years, Goodwin's European offices have grown from just 20 to more than 160 lawyers, including 15 dedicated to the technology and life sciences industry verticals. The firm's Europe-based lawyers are widely recognized across both transactional and fund formation practices in private equity, real estate, life sciences and technology industries. The London office is home to nearly 100 lawyers.

About Goodwin

At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility and ambition. Our 1,000-plus lawyers across the United States, Europe and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly-changing, technology-driven economy sets us apart. To learn more, visit us at www.goodwinlaw.com and follow us on Twitter, LinkedIn and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190618005506/en/

[ Back To TMCnet.com's Homepage ]